Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Trastuzumab Duocarmazine Active in HER2-Positive Breast Cancer

Jason Harris
Published: Thursday, Jun 21, 2018

breast cancer
The HER2-targeting antibody-drug conjugate (vic-)trastuzumab duocarmazine (SYD985) showed promising clinical activity in heavily-pretreated women with metastatic breast cancer, according to results from a phase I expansion cohort presented at the 2018 ASCO Annual Meeting.

The objective response rate (ORR) was 33% (16/48) among evaluable patients with HER2-positive disease, including 29% (11/38), among those who had prior T-DM1 (ado-trastuzumab emtansine; Kadcyla). The ORR was 27% (8/30) among evaluable patients with HER2-low/hormone receptor (HR)-positive disease, and 40% (6/15) for those with triple-negative disease. All responses across these subgroups were partial responses.

The median progression-free survival (PFS) was 9.4 months (95% CI, 4.5-12.4) overall in the HER2-positive group, and 8.3 months (95% CI, 4.1-15.0) among those in the group with prior T-DM1. The median PFS was 4.1 months (95% CI, 2.4-5.4) and 4.4 months (95% CI, 1.0-7.1) in the HER2-low/HR-positive and triple-negative arms, respectively.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x